摘要
目的回顾分析食管癌根治性调强放疗+化疗时放疗靶区范围对生存的影响。方法收集2006-2015年在河北医科大学第四医院行根治性调强放化疗的360例食管癌患者临床资料,其中选择性淋巴引流区照射(ENI)者131例,累及野照射(IFI)者229例。化疗均以铂类为基础的方案。采用Kaplan-Meier法计算总生存(OS)率并Logrank法检验。结果随访至2018年12月底,随访率96%,中位随访时间64个月(95%CI为53~76个月)。中位生存时间24.0个月(95%CI为19.77~28.23个月),1、3、5年OS率分别为76.1%、38.7%、21.0%。倾向评分配比法后均131例,ENI组和IFI组1、3、5年OS率分别为83.9%、48.6%、26.8%和74.0%、33.8%、17.5%(P=0.011)。亚组分析显示男性、年龄≤66岁、颈胸上段、肿瘤长度≤7 cm、肿瘤体积≤50 cm3、T1-3期、放疗剂量>60 Gy和同期放化疗者均可从ENI中获益(P<0.05)。ENI组总失败率、局部区域复发率和内脏转移率均低于IFI组(P<0.05),≥3级骨髓抑制高于IFI组(P<0.05)。结论食管癌患者接受根治性调强放化疗时,分期偏早及颈胸上段者可从ENI中获益。
Objective To evaluate the effects of different irradiation ranges in definitive intensity-modulated radiotherapy(IMRT)combined with chemotherapy on the survival of esophageal cancer patients.Methods Clinical data of 360 esophageal cancer patients who received definitive chemoradiotherapy in the Fourth Hospital of Hebei Medical University from 2006 to 2015 were retrospectively analyzed.Among them,131 patients received elective nodal irradiation(ENI)and 229 patients underwent involved-field irradiation(IFI).Platinum-based chemotherapy was adopted.The overall survival(OS)rate was analyzed by Kaplan-Meier method and Logrank test.Results Until the final follow-up at the end of December 2018,the follow-up rate was 96%.The median follow-up time was 64 months(95%CI:53-76).The median survival time was 24 months(95%CI:20-28).The 1-,3-,5-year OS rates were 76.1%,38.7%and 21.0%,respectively.After propensity score matching,the 1-,3-,5-year OS rates were 83.9%,48.6%,26.8%vs.74.0%,33.8%,17.5%between the ENI(n=131)and IFI groups(n=131)(P=0.011),respectively.Subgroup analysis showed that patients with male,aged≤66 years,cervical and upper-thoracic location,tumor length≤7cm,tumor volume≤50cm3,T1-3 stage,dosage>60Gy and concurrent chemoradiotherapy obtained better OS rates in the ENI group than their counterparts in the IFI group(all P<0.05).In the ENI group,the total failure rate,locoregional failure rate and distant metastasis rate were significantly lower,whereas the incidence of≥GradeⅢmyelosuppression was remarkably higher than those in the IFI group(all P<0.05).Conclusion Compared with IFI,ENI can significantly improve the survival for patients with early-stage and cervical and upper-thoracic esophageal cancer receiving definitive IMRT combined with chemotherapy.
作者
李巧芳
邓文钊
赵彦
宋春洋
许金蕊
王旋
祝淑钗
Li Qiaofang;Deng Wenzhao;Zhao Yan;Song Chunyang;Xu Jinrui;Wang Xuan;Zhu Shuchai(Department of Radiation Oncology,Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Oncology,Hebei General Hospital,Shijiazhuang 050011,China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2020年第7期513-518,共6页
Chinese Journal of Radiation Oncology
关键词
食管肿瘤/淋巴引流区预防照射
累及野照射
根治性放化疗
预后
Esophageal neoplasm/Elective nodal irradiation(ENI)
Involved-field irradiation(IFI)
Definitive chemoradiotherapy
Prognosis
